Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Moderate Impaired Hepatic Function as Defined by NCI-ODWG Criteria

Next Previous
Search
Trial Profile

An Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Moderate Impaired Hepatic Function as Defined by NCI-ODWG Criteria

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quizartinib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 24 Mar 2023 Results assessing the effects of quizartinib pharmacokinetics in mild or moderate hepatic impairment, data taken from two phase 1, open-label studies, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 16 Aug 2021 Status changed from active, no longer recruiting to completed.
  • 06 Jul 2021 Planned End Date changed from 14 Sep 2021 to 21 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top